Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maomei Ruan

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Medical Oncology (Northwood, London, England)|May 3, 2014
Update on the molecular diagnosis and targeted therapy of thyroid cancerMin Liu, Maomei Ruan, Libo Chen
Hellenic Journal of Nuclear Medicine|March 2, 2016
Challenges and strategies on radioiodine treatment for differentiated thyroid carcinomaLingxiao Cheng, Min Liu, Maomei Ruan, et al.
Oncology Letters|October 19, 2013
RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinomaMaomei Ruan, Yan Shen, Libo Chen, et al.
The Journal of Clinical Endocrinology and Metabolism|March 14, 2015
Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancerMaomei Ruan, Min Liu, Qianggang Dong, et al.
Thyroid : Official Journal of the American Thyroid Association|April 2, 2014
Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinomaMin Liu, Yan Shen, Maomei Ruan, et al.
Medicine|September 8, 2016
Increased 18F-FDG uptake of heterotopic pancreatitis in the small intestine: A CARE-compliant case reportMaomei Ruan, Min Liu, Lingxiao Cheng, et al.
Oncotarget|April 21, 2017
HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600ELingxiao Cheng, Yuchen Jin, Min Liu, et al.
Scientific Reports|March 14, 2018
Predicting <sup>131</sup>I-avidity of metastases from differentiated thyroid cancer using <sup>18</sup>F-FDG PET/CT in postoperative patients with elevated thyroglobulinMin Liu, Lingxiao Cheng, Yuchen Jin, et al.
Medicine|August 18, 2017
99mTc-pertechnetate-avid metastases from differentiated thyroid cancer are prone to benefit from 131I therapy: A prospective observational studyMin Liu, Li Chai, Qiong Luo, et al.
Thyroid : Official Journal of the American Thyroid Association|December 19, 2018
Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled TrialYuchen Jin, Maomei Ruan, Lingxiao Cheng, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Medical Oncology (Northwood, London, England)|May 3, 2014
Update on the molecular diagnosis and targeted therapy of thyroid cancerMin Liu, Maomei Ruan, Libo Chen
Hellenic Journal of Nuclear Medicine|March 2, 2016
Challenges and strategies on radioiodine treatment for differentiated thyroid carcinomaLingxiao Cheng, Min Liu, Maomei Ruan, et al.
Oncology Letters|October 19, 2013
RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinomaMaomei Ruan, Yan Shen, Libo Chen, et al.
The Journal of Clinical Endocrinology and Metabolism|March 14, 2015
Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancerMaomei Ruan, Min Liu, Qianggang Dong, et al.
Thyroid : Official Journal of the American Thyroid Association|April 2, 2014
Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinomaMin Liu, Yan Shen, Maomei Ruan, et al.
Medicine|September 8, 2016
Increased 18F-FDG uptake of heterotopic pancreatitis in the small intestine: A CARE-compliant case reportMaomei Ruan, Min Liu, Lingxiao Cheng, et al.
Oncotarget|April 21, 2017
HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600ELingxiao Cheng, Yuchen Jin, Min Liu, et al.
Scientific Reports|March 14, 2018
Predicting <sup>131</sup>I-avidity of metastases from differentiated thyroid cancer using <sup>18</sup>F-FDG PET/CT in postoperative patients with elevated thyroglobulinMin Liu, Lingxiao Cheng, Yuchen Jin, et al.
Medicine|August 18, 2017
99mTc-pertechnetate-avid metastases from differentiated thyroid cancer are prone to benefit from 131I therapy: A prospective observational studyMin Liu, Li Chai, Qiong Luo, et al.
Thyroid : Official Journal of the American Thyroid Association|December 19, 2018
Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled TrialYuchen Jin, Maomei Ruan, Lingxiao Cheng, et al.
Pageof 3